The importance of MCL-1 in breast cancer has also emerged from new models that recapitulate the genetic events in BRCA1-mutant tumors, where loss-of-function mutations in TP53 and amplification of MYC occur in 65% and 44% of cases, respectively [124]. This evidence concerns the gene BRCA1 and breast carcinoma.